PROBODY

Welcome to the Brand page for “PROBODY”, which is offered here for Engineered cell therapies for medical purposes, for use in treating cancer;pro body;biochemicals, proteolytically-activatable or protease-activatable, or proteolytically activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue; diagnostic and therapeutic kits consisting of proteolytically-activatable or protease-activatable, or proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue; immunoglobulin for drug conjugation and targeted cell binding for laboratory and research use;scientific research and development in the field of therapeutic biochemicals, engineered cell therapies and immunotherapy; medical and scientific research and development for agents, preparations, products and technology in the field of dysregulated proteolytic activities; providing medical and scientific research information in the fields of biochemicals, engineered cell therapies, immunotherapy, oncology and dysregulated proteolytic activity; scientific investigations for medical purposes; medical research;.

Its status is currently believed to be active. Its class is unavailable. “PROBODY” is believed to be currently owned by “CytomX Therapeutics, Inc.”